RPL22B Antibody

What is RPL22 and what are its primary functions in cellular biology?

RPL22 is a ribosomal protein that functions as a component of the 60S large ribosomal subunit and plays a role in protein translation. Beyond its structural role in ribosomes, RPL22 has been identified to associate with both viral RNAs (like EBER1) and cellular RNAs (such as human telomerase RNA). Importantly, RPL22 functions as a direct regulator of its paralog RPL22L1, acting to repress its expression through direct binding to RPL22L1 mRNA . The protein has been found to be mutated or downregulated in various cancers, including T-acute lymphoblastic leukemias, invasive breast carcinoma, and lung adenocarcinoma, suggesting its potential role as a tumor suppressor .

What are the recommended applications for RPL22 antibody (25002-1-AP)?

The RPL22 antibody (25002-1-AP) is validated for multiple applications including Western Blot (WB), Immunoprecipitation (IP), Immunofluorescence (IF)/Immunocytochemistry (ICC), and ELISA. It has been tested for reactivity with human samples and cited for reactivity with both human and mouse samples . For optimal results, researchers should use specific dilutions for each application: 1:500-1:1000 for WB, 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate in IP, and 1:50-1:500 for IF/ICC applications .

What is the relationship between RPL22 and RPL22L1?

RPL22 and RPL22L1 exist as paralogs with highly homologous protein sequences. Research demonstrates that RPL22 negatively regulates the expression of RPL22L1 at both the mRNA and protein levels. Knockout or knockdown of RPL22 results in significant upregulation of RPL22L1, suggesting a compensatory mechanism . This relationship is biologically significant as RPL22L1 can co-sediment with actively translating ribosomes in RPL22-deficient mice, likely accounting for the lack of translational defects in these animals despite RPL22 deletion . Recent findings identify RPL22 and RPL22L1 as a synthetic lethal paralog pair, indicating their coordinated function in cellular processes .

How does RPL22 mechanistically regulate RPL22L1 expression?

RPL22 regulates RPL22L1 through direct binding to RPL22L1 mRNA. Analysis using M-fold algorithm has revealed a consensus RPL22 RNA-binding motif within exon 2 of RPL22L1 mRNA . RPL22 recognizes a stem loop (hairpin) structure with a G-C at the neck followed by a U nucleotide in the RNA secondary structure . This binding appears to affect RPL22L1 mRNA stability, as demonstrated by actinomycin D experiments showing significantly decreased RPL22L1 mRNA decay rates in RPL22-deficient cells compared to wild-type controls . This direct regulatory mechanism represents an unusual example of one ribosomal protein controlling the expression of its paralog, potentially fine-tuning ribosome composition in response to cellular needs.

What is the significance of RPL22 frameshift mutations in cancer research?

RPL22 frameshift mutations, particularly the RPL22K15Rfs hotspot mutation, have been identified as key markers of sensitivity to RNA polymerase I (Pol I) inhibitors in microsatellite instable (MSI) cancers . This mutation affects up to 70% of MSI cancer cell lines and dMMR (deficient mismatch repair) tumors . The mechanistic significance lies in how RPL22 deficiency alters ribotoxic stress responses. RPL22 functions as a splicing regulator through direct interactions with 28S rRNA and mRNA splice junctions, and its loss disrupts this regulatory network . Cancer researchers studying MSI tumors should consider RPL22 mutation status when evaluating potential therapeutic approaches, particularly those targeting ribosome biogenesis pathways.

How does rRNA transcription connect to splicing through RPL22?

Recent research has uncovered a novel mechanism where RPL22 coordinates rRNA synthesis with splicing programs. High rRNA synthesis activity sequesters RPL22 into ribosomes, countering its splicing regulatory functions . When RNA polymerase I (Pol I) is inhibited, changes occur in the splicing of numerous mRNAs, particularly RPL22L1 and MDM4, through an RPL22-dependent mechanism . This reveals a molecular connection between rRNA synthesis activity and post-transcriptional/spliceosomal control, with significant implications for understanding cancer biology. RPL22 essentially functions as a molecular switch that responds to cellular rRNA production rates and subsequently regulates splicing programs.

What are the optimal protocols for using RPL22 antibody in Western Blot experiments?

For Western Blot applications with RPL22 antibody (25002-1-AP), researchers should use a dilution range of 1:500-1:1000 . The antibody has been validated to detect RPL22 in multiple human cell lines including A431, HeLa, HepG2, and Jurkat cells . The observed molecular weight of RPL22 is typically 15-18 kDa, which aligns with its calculated molecular weight of 15 kDa . For optimal results, researchers should carefully follow the manufacturer's WB protocol specific to this antibody, which includes detailed steps for sample preparation, protein separation, transfer, blocking, and detection. It's recommended to titrate the antibody concentration in each testing system to achieve optimal signal-to-noise ratio.

How can researchers effectively design RPL22 knockdown experiments?

Based on published research, effective RPL22 knockdown can be achieved using lentiviral-mediated inducible systems. Researchers have successfully employed tet-on shRNA lentivirus constructs targeting RPL22 mRNA . When designing such experiments, it's important to include appropriate controls, such as non-specific shRNA constructs. The knockdown efficiency should be verified at both mRNA and protein levels using RT-qPCR and Western blot, respectively. Researchers should anticipate and monitor compensatory increases in RPL22L1 expression following RPL22 knockdown . For acute knockdown studies examining regulatory mechanisms, doxycycline-inducible systems allow for temporal control of RPL22 expression to distinguish between direct regulatory effects and adaptive compensatory responses.

What methods can be used to study RPL22-RNA interactions?

To investigate RPL22 binding to target RNAs, researchers have employed several approaches. RNA secondary structure prediction tools like M-fold algorithm can be used to identify potential RPL22 binding motifs in target transcripts, focusing on stem loop structures with G-C at the neck followed by a U nucleotide . RNA immunoprecipitation (RIP) assays can confirm direct binding of RPL22 to target RNAs in cellular contexts. For analyzing the impact of these interactions on RNA stability, actinomycin D treatment combined with time-course RT-qPCR provides insights into decay rates in the presence or absence of RPL22 . More advanced techniques such as CLIP-seq (Cross-linking immunoprecipitation followed by sequencing) could be employed to map RPL22 binding sites transcriptome-wide.

What are common issues with RPL22 antibody specificity and how can they be addressed?

When working with RPL22 antibody, researchers might encounter specificity concerns due to the high homology between RPL22 and its paralog RPL22L1. To ensure specificity, validation experiments should include appropriate controls such as RPL22 knockout/knockdown samples . The antibody (25002-1-AP) has been verified to detect RPL22 at the expected molecular weight of 15-18 kDa . If cross-reactivity is suspected, researchers should optimize antibody dilution, blocking conditions, and washing steps. Additionally, pre-absorption with recombinant RPL22L1 protein could be performed to assess potential cross-reactivity. Western blot analysis should include other ribosomal proteins as controls (e.g., RPL7) to confirm specificity of observed changes in expression patterns .

How can researchers distinguish between direct RPL22 effects and compensatory mechanisms in functional studies?

Distinguishing direct regulatory effects of RPL22 from compensatory responses requires careful experimental design. Acute inducible knockdown systems, as demonstrated with doxycycline-inducible shRNA targeting RPL22, provide temporal resolution to identify immediate consequences of RPL22 loss versus long-term adaptations . Time-course analyses following RPL22 depletion can reveal the kinetics of RPL22L1 upregulation. Direct molecular interactions should be confirmed through techniques such as RNA immunoprecipitation to demonstrate RPL22 binding to target RNAs . For functional studies, complementation experiments reintroducing wild-type or mutant RPL22 into knockout backgrounds can help establish causality. Researchers should also consider analyzing additional ribosomal proteins to determine the specificity of observed effects on RPL22L1 .

What considerations are important when studying RPL22 in different cell types and tissues?

The biological effects of RPL22 vary across different cell types and tissues. Most notably, while RPL22 knockout mice are viable, they exhibit specific defects in T cell development attributed to p53-dependent arrest of αβ lineage T cells . B cell development is also interrupted by RPL22 deficiency, with decreased B220+ developing B cells in the bone marrow . When investigating RPL22 functions, researchers should consider tissue-specific expression patterns of both RPL22 and RPL22L1. The compensatory increase in RPL22L1 following RPL22 loss may vary between tissues, influencing the phenotypic consequences. Quantitative mass spectrometry approaches like Multiple Reaction Monitoring (MRM) can be used to measure the relative amounts of RPL22 and RPL22L1 in ribosome fractions from different tissues .

How does RPL22 deficiency influence sensitivity to RNA polymerase I inhibitors?

Recent research has revealed that RPL22 frameshift mutations confer sensitivity to RNA polymerase I (Pol I) inhibitors in microsatellite instable cancers . The mechanism involves RPL22's role as a splicing regulator through its interactions with 28S rRNA and mRNA splice junctions. RPL22 deficiency, when intensified by 28S rRNA sequestration, affects the splicing of multiple transcripts . Knockdown experiments with RPL22, MDM4, and RPL22L1 each led to significant resistance to Pol I inhibition, suggesting a complex interplay between these factors . Cancer researchers investigating novel therapeutic approaches should consider RPL22 mutation status as a potential biomarker for response to Pol I inhibitors such as BMH-21 and its optimized derivative BOB-42, which have shown efficacy in preclinical models .

What is the potential role of RPL22 and RPL22L1 in cancer development and progression?

RPL22 has been identified as a potential tumor suppressor, with mutations or downregulation observed in T-acute lymphoblastic leukemias, invasive breast carcinoma, and lung adenocarcinoma . The RPL22K15Rfs hotspot mutation is present in up to 70% of microsatellite instable cancer cell lines and deficient mismatch repair tumors . The relationship between RPL22 and RPL22L1 may have significant implications for cancer biology, as they function as a synthetic lethal paralog pair . The upregulation of RPL22L1 in RPL22-deficient contexts suggests potential oncogenic functions for RPL22L1. Researchers investigating cancer mechanisms should consider both proteins' expression levels and mutational status, particularly in microsatellite instability contexts where RPL22 frameshift mutations are common .

What are the key considerations for researchers using RPL22 antibodies in their studies?

Researchers utilizing RPL22 antibodies should carefully consider several factors to ensure experimental success. First, the selection of appropriate applications (WB, IP, IF/ICC) with recommended dilutions is crucial . Second, the high homology between RPL22 and RPL22L1 necessitates careful validation of antibody specificity. Third, the interdependent regulation between RPL22 and RPL22L1 means that manipulation of one will likely affect the other, requiring monitoring of both proteins in experimental designs . Fourth, tissue-specific effects of RPL22 deficiency suggest the importance of cell type selection in research models. Finally, the emerging connections between RPL22, splicing regulation, and rRNA synthesis point to broader roles beyond ribosomal structure, opening new avenues for investigation in both basic science and cancer research contexts .